Literature DB >> 9731023

Nasal potential difference in congenital bilateral absence of the vas deferens.

U Pradal1, C Castellani, A Delmarco, G Mastella.   

Abstract

Congenital bilateral absence of the vas deferens (CBAVD) is supposed to be due to defective activity of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) in the genital tract. With the aim of studying CFTR activity in vivo we measured nasal potential difference (NPD) in a group of CBAVD subjects, who were then compared with normal control subjects and CF patients. Sodium transport, measured under basal conditions and after amiloride superinfusion, was normal in almost all CBAVD patients, who had NPD values similar to those of normal control subjects. Chloride transport was studied by measuring NPD during perfusion with a chloride-free solution and isoproterenol. Under these circumstances CBAVD patients as a whole showed normal chloride secretion. However, three subjects with CBAVD had abnormal NPD values. They had either elevated sweat chloride concentrations together with symptoms of mild CF, or compound heterozygosity (DeltaF508/R117H). In conclusion the group of CBAVD patients as a whole presented normal bioelectric properties of nasal epithelium, suggesting normal CFTR activity. In a small subgroup NPD was abnormal, suggesting a diagnosis of CF, later confirmed by elevated sweat chloride concentrations or positive DNA testing. We suggest that CBAVD patients with altered NPD should undergo further clinical follow-up in order to detect possible late complications of CF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731023     DOI: 10.1164/ajrccm.158.3.9711029

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  4 in total

Review 1.  The pathogenic consequences of a single mutated CFTR gene.

Authors:  U Griesenbach; D M Geddes; E W Alton
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Protracted neonatal hypertrypsinogenaemia, normal sweat chloride, and cystic fibrosis.

Authors:  C Castellani; A Tamanini; G Mastella
Journal:  Arch Dis Child       Date:  2000-06       Impact factor: 3.791

3.  Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.

Authors:  Michael Wilschanski; Annie Dupuis; Lynda Ellis; Keith Jarvi; Julian Zielenski; Elizabeth Tullis; Sheelagh Martin; Mary Corey; Lap-Chee Tsui; Peter Durie
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

4.  Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Authors:  Frank J Accurso; Fredrick Van Goor; Jiuhong Zha; Anne J Stone; Qunming Dong; Claudia L Ordonez; Steven M Rowe; John Paul Clancy; Michael W Konstan; Heather E Hoch; Sonya L Heltshe; Bonnie W Ramsey; Preston W Campbell; Melissa A Ashlock
Journal:  J Cyst Fibros       Date:  2014-03       Impact factor: 5.527

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.